153 related articles for article (PubMed ID: 21706270)
1. Formulation and stability testing of itraconazole crystalline nanoparticles.
Badawi AA; El-Nabarawi MA; El-Setouhy DA; Alsammit SA
AAPS PharmSciTech; 2011 Sep; 12(3):811-20. PubMed ID: 21706270
[TBL] [Abstract][Full Text] [Related]
2. Formulation and drying of miconazole and itraconazole nanosuspensions.
Cerdeira AM; Mazzotti M; Gander B
Int J Pharm; 2013 Feb; 443(1-2):209-20. PubMed ID: 23291552
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Solid Dispersion of Itraconazole Prepared by Solubilization in Concentrated Aqueous Solutions of Weak Organic Acids and Drying.
Parikh T; Sandhu HK; Talele TT; Serajuddin AT
Pharm Res; 2016 Jun; 33(6):1456-71. PubMed ID: 26951566
[TBL] [Abstract][Full Text] [Related]
4. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.
Mou D; Chen H; Wan J; Xu H; Yang X
Int J Pharm; 2011 Jul; 413(1-2):237-44. PubMed ID: 21540090
[TBL] [Abstract][Full Text] [Related]
5. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension.
Zhang K; Yu H; Luo Q; Yang S; Lin X; Zhang Y; Tian B; Tang X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1285-92. PubMed ID: 23562534
[TBL] [Abstract][Full Text] [Related]
6. Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs.
Yin X; Daintree LS; Ding S; Ledger DM; Wang B; Zhao W; Qi J; Wu W; Han J
Drug Des Devel Ther; 2015; 9():2801-10. PubMed ID: 26060397
[TBL] [Abstract][Full Text] [Related]
7. Development of stabilized itraconazole nanodispersions by using high-gravity technique.
Zhang ZL; Le Y; Wang JX; Zhao H; Chen JF
Drug Dev Ind Pharm; 2012 Dec; 38(12):1512-20. PubMed ID: 22435399
[TBL] [Abstract][Full Text] [Related]
8. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Pharm; 2012 May; 428(1-2):103-13. PubMed ID: 22414388
[TBL] [Abstract][Full Text] [Related]
9. Ternary Amorphous Solid Dispersions Containing a High-Viscosity Polymer and Mesoporous Silica Enhance Dissolution Performance†.
Hanada M; Jermain SV; Thompson SA; Furuta H; Fukuda M; Williams RO
Mol Pharm; 2021 Jan; 18(1):198-213. PubMed ID: 33291881
[TBL] [Abstract][Full Text] [Related]
10. Alternative matrix formers for nanosuspension solidification: Dissolution performance and X-ray microanalysis as an evaluation tool for powder dispersion.
Van Eerdenbrugh B; Froyen L; Van Humbeeck J; Martens JA; Augustijns P; Van Den Mooter G
Eur J Pharm Sci; 2008 Nov; 35(4):344-53. PubMed ID: 18765282
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the formulation of solid dispersions by co-spray drying itraconazole with Inutec SP1, a polymeric surfactant, in combination with PVPVA 64.
Janssens S; Humbeeck JV; Van den Mooter G
Eur J Pharm Biopharm; 2008 Oct; 70(2):500-5. PubMed ID: 18582567
[TBL] [Abstract][Full Text] [Related]
12. Application of pharmaceutical QbD for enhancement of the solubility and dissolution of a class II BCS drug using polymeric surfactants and crystallization inhibitors: development of controlled-release tablets.
Basalious EB; El-Sebaie W; El-Gazayerly O
AAPS PharmSciTech; 2011 Sep; 12(3):799-810. PubMed ID: 21701960
[TBL] [Abstract][Full Text] [Related]
13. Single-step preparation and deagglomeration of itraconazole microflakes by supercritical antisolvent method for dissolution enhancement.
Sathigari SK; Ober CA; Sanganwar GP; Gupta RB; Babu RJ
J Pharm Sci; 2011 Jul; 100(7):2952-65. PubMed ID: 21344415
[TBL] [Abstract][Full Text] [Related]
14. Development of stability-enhanced ternary solid dispersions via combinations of HPMCP and Soluplus
Albadarin AB; Potter CB; Davis MT; Iqbal J; Korde S; Pagire S; Paradkar A; Walker G
Int J Pharm; 2017 Oct; 532(1):603-611. PubMed ID: 28923766
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs.
Van den Mooter G; Weuts I; De Ridder T; Blaton N
Int J Pharm; 2006 Jun; 316(1-2):1-6. PubMed ID: 16563676
[TBL] [Abstract][Full Text] [Related]
16. Formulating Amorphous Solid Dispersions: Impact of Inorganic Salts on Drug Release from Tablets Containing Itraconazole-HPMC Extrudate.
Takano R; Maurer R; Jacob L; Stowasser F; Stillhart C; Page S
Mol Pharm; 2020 Aug; 17(8):2768-2778. PubMed ID: 31794228
[TBL] [Abstract][Full Text] [Related]
17. Enhanced pulmonary absorption of poorly soluble itraconazole by micronized cocrystal dry powder formulations.
Karashima M; Sano N; Yamamoto S; Arai Y; Yamamoto K; Amano N; Ikeda Y
Eur J Pharm Biopharm; 2017 Jun; 115():65-72. PubMed ID: 28223260
[TBL] [Abstract][Full Text] [Related]
18. Production of Irbesartan Nanocrystals by High Shear Homogenisation and Ultra-Probe Sonication for Improved Dissolution Rate.
Sridhar K; Rahman H; Sosnik A; Mukherjee U; Natarajan T; Siram K; Krishnamoorthy B
Curr Drug Deliv; 2016; 13(5):688-97. PubMed ID: 26563944
[TBL] [Abstract][Full Text] [Related]
19. Curcumin nanoparticles containing poloxamer or soluplus tailored by high pressure homogenization using antisolvent crystallization.
Homayouni A; Amini M; Sohrabi M; Varshosaz J; Nokhodchi A
Int J Pharm; 2019 May; 562():124-134. PubMed ID: 30898640
[TBL] [Abstract][Full Text] [Related]
20. Hot-melt extrusion for enhanced delivery of drug particles.
Miller DA; McConville JT; Yang W; Williams RO; McGinity JW
J Pharm Sci; 2007 Feb; 96(2):361-76. PubMed ID: 17075869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
